PMID- 18547172
OWN - NLM
STAT- MEDLINE
DCOM- 20080815
LR  - 20161124
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 34 Suppl 1
DP  - 2008 Jun
TI  - Minimizing adverse events associated with poly-L-lactic acid injection.
PG  - S100-4
LID - 10.1111/j.1524-4725.2008.34250.x [doi]
AB  - BACKGROUND Injectable devices offer an attractive alternative to surgical 
      cosmetic rejuvenation. Many injectable products are biocompatible but demonstrate 
      varying levels of durability, ranging from temporary to permanent. Product 
      duration is determined, in part, by its mode of operation. Passive fillers, such 
      as collagen, generally add volume through mass, whereas other injectables, such 
      as poly-L-latic acid (PLLA), rely on a foreign-body response in which endogenous 
      collagen production by fibroblasts is thought to generate new volume. OBJECTIVE 
      To review the use of injectable PLLA, specifically regarding optimal injection 
      technique that can reduce adverse events (AEs) and enhance out comes. RESULTS 
      PLLA has been used extensively to correct HIV-related facial lipoatrophy, with 
      effects lasting for up to 2 years. The efficacy and safety of PLLA can be 
      influenced by correct product reconstitution, dilution, and administration. 
      Undesired AEs, such as papules and nodules, may result from incorrect 
      reconstitution, uneven product distribution in the suspension, imprecise 
      injection technique (superficial injection), or lack of posttreatment massage. 
      CONCLUSION Administration of PLLA with optimal techniques can help enhance 
      treatment effect while simultaneously minimizing AES.
FAU - Narins, Rhoda S
AU  - Narins RS
AD  - Dermatology Surgery and Laser Center, New York, USA. rsnmd@worldnet.att.net
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (New-Fill)
RN  - 0 (Polyesters)
RN  - 0 (Polymers)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 3OWL53L36A (Mannitol)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 9004-34-6 (Cellulose)
SB  - IM
MH  - Cellulose/administration & dosage/*adverse effects
MH  - Cosmetic Techniques/*adverse effects
MH  - Drug Compounding
MH  - Face/pathology
MH  - Female
MH  - Granuloma, Foreign-Body/chemically induced
MH  - HIV-Associated Lipodystrophy Syndrome/therapy
MH  - Humans
MH  - Hypersensitivity, Delayed/chemically induced
MH  - Injections, Subcutaneous/adverse effects/methods
MH  - Lactic Acid/administration & dosage/*adverse effects
MH  - Mannitol/administration & dosage/*adverse effects
MH  - Massage
MH  - Polyesters
MH  - Polymers/administration & dosage/*adverse effects
MH  - Skin/pathology
MH  - Skin Aging
MH  - Skin Diseases/chemically induced/*prevention & control
RF  - 18
EDAT- 2008/07/02 09:00
MHDA- 2008/08/16 09:00
CRDT- 2008/07/02 09:00
PHST- 2008/07/02 09:00 [pubmed]
PHST- 2008/08/16 09:00 [medline]
PHST- 2008/07/02 09:00 [entrez]
AID - DSU34250 [pii]
AID - 10.1111/j.1524-4725.2008.34250.x [doi]
PST - ppublish
SO  - Dermatol Surg. 2008 Jun;34 Suppl 1:S100-4. doi: 10.1111/j.1524-4725.2008.34250.x.